Short Communication: Emerging Transmitted HIV Type 1 Drug Resistance Mutations Among Patients Prior to Start of First-Line Antiretroviral Therapy in Middle and Low Prevalence Sites in China

Abstract

It is known that transmitted drug resistance (TDR) will most likely emerge in regions where antiretroviral therapy (ART) has been widely available for years. However, after a decade of rapid scale-up of ART in China, there are few data regarding TDR among HIV-infected patients prior to initiating first-line ART in China. A prospective, observational cohort study was performed at sentinel sites in five provinces or municipalities. Study participants were recruited at the county- or city-level centers for disease control (CDCs), during routine monitoring visits following referral from diagnosing parties (e.g., hospitals). Each province or municipality recruited 140 patients through sequential sampling throughout the 2011 calendar year. A total of 627 eligible subjects were included in the analysis. the median CD4⁺ cell count was 206 cells/ml at the baseline survey. The majority of patients (93.5%) had plasma HIV viral load ≥1,000 copies/ml. Of the 627 patients, 17 (2.7%) had drug resistance mutations for any type of HIV drugs. The prevalence of drug resistance mutations to nonnucleoside reverse transcriptase inhibitor (NNRTI) drugs (8/627, 1.3%) was higher than to nucleoside reverse transcriptase inhibitor (NRTI) drugs (5/627, 0.8%) and protease inhibitor (PI) drugs (4/627, 0.6%). A logistic regression model showed that the only predictive factor was the route of infection through homosexual intercourse, i.e., men who have sex with men (MSM) status. As HIV prevalence is rising rapidly among Chinese MSM, it is essential to continue surveying this risk group and related high-risk populations with low awareness of HIV, and to develop new public health interventions that help to reduce the spread of drug-resistant HIV.

Get full access to this article

View all access options for this article.

References

Liu

, Shafer

. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis, 2006; 42,11:1608–1618.

Zhong

, Pan

, Ning

et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses, 2007; 23,7:847–856.

Liao

, Xing

, Shang

et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr, 2010; 53,Suppl 1:S10–14.

Dou

, Chen

, Xu

et al. Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002–09. Int J Epidemiol, 2010; 39,Suppl 2:ii56–64.

Qian

, Vermund

, Kaslow

et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: Challenge for patient care in rural China. AIDS, 2006; 20,10:1429–1435.

, Zhang

, He

et al. Trends in prevalence of HIV, syphilis, hepatitis C, hepatitis B, and sexual risk behavior among men who have sex with men. Results of 3 consecutive respondent-driven sampling surveys in Beijing, 2004 through 2006. J Acquir Immune Defic Syndr, 2007; 45,5:581–587.

Ruan

, Pan

, Chamot

et al. Sexual mixing patterns among social networks of HIV-positive and HIV-negative Beijing men who have sex with men: A multilevel comparison using roundtable network mapping. AIDS Care, 2011; 23,8:1014–1025.

Yan

, Yang

, Zhao

et al. Long-chain peer referral of men who have sex with men: A novel approach to establish and maintain a cohort to measure HIV incidence, Nanjing, China. J Acquir Immune Defic Syndr, 2012; 59,2:177–184.

Goldsamt

, Clatts

, Parker

et al. Prevalence of sexually acquired antiretroviral drug resistance in a community sample of HIV-positive men who have sex with men in New York City. AIDS Patient Care STDS, 2011; 25,5:287–293.